FIERCELY FOCUSED
ON SCIENCE

OUR PIPELINE

MS

ONCOLOGY
REGIMEN DIsease Preclinical Phase 1 Phase 2 Phase 3 Registration Status Learn More

Single Agent

Ublituximab monotherapy: anti-CD20 mAb Relapsing MS
ULTIMATE I and II
learnmore
Umbralisib monotherapy: P13k-delta & CK1-epsilon inhibitor R/R MZL
UNITY-NHL
NOW APPROVED learnmore
Umbralisib monotherapy R/R FL
UNITY-NHL
NOW APPROVED learnmore

Combination

Umbralisib + ublituximab (U2) R/R NHL
UNITY-NHL
learnmore
Umbralisib + ublituximab (U2) TN and R/R CLL
UNITY-CLL
learnmore
Ublituximab + ibrutinib R/R high-risk CLL
GENUINE
learnmore
Umbralisib + ublituximab + venetoclax TN and R/R CLL
ULTRA-V
learnmore
Umbralisib + ublituximab + TG-1701 (BTKi) TN and R/R CLL & NHL
learnmore

Early Pipeline

Cosibelimab (TG-1501): anti-PD-L1 mAb B-cell malignancies
learnmore
TG-1701: BTK inhibitor B-cell malignancies
learnmore
TG-1801: anti-CD47/CD19 bispecific mAb B-cell malignancies
learnmore
TG-1601: BET inhibitor B-cell malignancies
learnmore
ENROLLMENT COMPLETED
ENROLLMENT ONGOING

R/R=relapsed or refractory; TN=treatment naive.

The safety and efficacy of our investigational compounds have not been established. These products have not been approved by the US Food and Drug Administration or other regulatory authorities.

ENROLLMENT COMPLETED
ENROLLMENT ONGOING

Single Agent

REGIMEN Preclinical Phase 1 Phase 2 Phase 3

MS

Ublituximab monotherapy: anti-CD20 mAb

DiseaseRelapsing MS

Learn More learnmore

ULTIMATE I and II
ONCOLOGY
Umbralisib monotherapy: P13k-delta & CK1 -epsilon inhibitor

DiseaseR/R MZL

Learn More learnmore

UNITY-NHL

PDUFA: 2/15/2021

Umbralisib + Ublituximab (U2)

DiseaseR/R FL

Learn More learnmore

UNITY-NHL

PDUFA: 6/15/2021

EARLY PIPELINE

REGIMEN Preclinical Phase 1 Phase 2 Phase 3
ONCOLOGY
Cosibelimab (TG-1501): anti-PD-L1 mAb

DiseaseB-cell malignancies

Learn More learnmore

TG-1701: BTK inhibitor

DiseaseB-cell malignancies

Learn More learnmore

TG-1801: anti-CD47/CD19 bispecific mAb

DiseaseB-cell malignancies

Learn More learnmore

TG-1601: BET inhibitor

DiseaseB-cell malignancies

Learn More learnmore

R/R=relapsed or refractory; TN=treatment naive.

The safety and efficacy of our investigational compounds have not been established. These products have not been approved by the US Food and Drug Administration or other regulatory authorities.